

ML213

Catalog No: tcsc6933

Available Sizes

Size: 5mg

Size: 25mg

Size: 50mg

Size: 100mg

Size: 100mg

Specifications

Formula:

 $C_{17}H_{23}NO$

Pathway: Membrane Transporter/Ion Channel

Target: Potassium Channel

Purity / Grade:

>98%

Solubility:

DMSO : 30 mg/mL (116.56 mM; Need ultrasonic and warming)

Observed Molecular Weight:

257.37

Copyright 2021 Taiclone Biotech Corp.



Product Description

ML213 is a selective activator of **Kv7.2** and **Kv7.4** channels, enhances Kv7.2 and Kv7.4 channels with **EC**₅₀s of 230 and 510 nM, respectively.

IC50 & Target: EC50: 230 nM (Kv7.2 channel), 510 nM (Kv7.4 channel)^{[2][3]}

In Vitro: ML213 (100 nM-30 μ M) increases maximal conductance to a peak at 212% ± 27% of control, with an EC₅₀ of 0.8 ± 0.3 μ M. ML213 (10 μ M) reduces the deactivation rates of Kv7.4 currents by 4.6-fold in the voltage range from –130 mV to –90 mV. ML213 is a potent and effective activator of homomeric Kv7.5 channels overexpressed in A7r5 cells. ML213 increases maximal conductance of Kv7.5 channels with an EC₅₀ of 0.7 ± 0.2 μ M. ML213 (10 μ M) also reduces deactivation rates of Kv7.5 currents by 5.9-fold on average. ML213 produces similar effects on heteromeric Kv7.4/7.5 channels: 204% ± 11% maximal increase in conductance with an EC₅₀ of 1.1 ± 0.6 μ M and a 34.2 ± 3.3 mV maximal negative shift of the activation curve, with an EC₅₀ of 3.8 ± 1.2 μ M^[1]. ML213 causes a vasorelaxation in different precontracted rat blood vessels. ML213 (10 μ M) also hyperpolarizes mesenteric artery smooth muscle cells^[2]. ML213 causes a concentration-dependent shift in the V1/2 for KCNQ2 activation with an EC₅₀ 340 ± 70 nM and a maximal shift of 37.4 mV^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.